|
28/06/2007- Regular
consumption of sea buckthorn berries reduced levels of a protein
that is associated with inflammation, diabetes and heart
disease, say Finnish scientists.
However,
no major effects were observed on the instance of common cold or
digestive tract infections, reports the study published in the European
Journal of Clinical Nutrition.
The
report could see the berries join an ever-increasing list of a
number of antioxidant fruits, including pomegranate, guarana,
mangosteen, noni berries, goji berries and blueberries, which
are increasingly seen by food and beverage makers as up and
coming ingredients.
Indeed,
Leatherhead Foods predicts that sales of such heart health foods
will rise nearly 60 per cent over the 2004-2009 period to reach
nearly €4.2bn ($5.7bn) by 2009.
"Sea buckthorn berries did not prevent common cold or
digestive tract infections. However, a reductive effect on CRP,
a marker of inflammation, and a risk factor for cardiovascular
diseases, was detected," wrote lead author Petra Larmo from the
University of Turku.
C-reactive
protein (CRP) is produced in the liver and is a known marker for
inflammation. Increased levels of CRP are a good predictor for
the onset of both type-2 diabetes and cardiovascular disease.
An
estimated 19 million people are affected by diabetes in the EU
25, projected to increase to 26 million by 2030. CVD causes
almost 50 per cent of deaths in Europe, and is reported to cost
the EU economy an estimated €169 billion ($202 billion) per
year.
The
researchers recruited 233 healthy subjects (average age 30.7,
average BMI 23.1 kg per sq. m) and randomly assigned them to
receive sea buckthorn or placebo product for 90 days.
Petra
Larmo told NutraIngredients.com: "The daily
berry dose was 28 g (frozen sea buckthorn berry puree). The
daily dose contained 16.7 mg flavonol glycosides (the glycosides
of isorhamnetin were the most abundant), 15.6 mg vitamin C, and
1.1 mg alpha-tocopherol. Calculated as aglycones the total daily
amount of flavonols was about 8.4 mg.
"A moderate berry dose was chosen to have a realistic
dose for everyday consumption of the average person,"
she added.
At
the end of the study, Larmo and co-workers report that no
significant difference in the number or duration of common cold
or digestive tract infections between the sea buckthorn and
placebo groups.
For
levels of CRP, however, significant differences were observed
between the groups. Consumption of sea buckthorn was associated
with an average 0.059 mg/l decrease, which suggests beneficial
effects for cardiovascular health.
The
number of UTI was too small to draw solid conclusions, but the
results indicate the subject merits further investigation.
"We are carrying on our studies concerning the health
effects of sea buckthorn berry. We analysed the samples of the
trial reported in the EJCN for other risk markers of
cardiovascular disease and flavonols, and are currently writing
a manuscript of these results,"
Larmo told this website.
"Several other analyses (markers of inflammation,
endothelium dysfunction and oxidation) from these samples have
also been made and will be reported later. At the end of this
year, we are planning on starting a new clinical trial. The
objective is to study the effects of sea buckthorn berry on
urinary tract (and other) infections in elderly people,"
she added.
Back
in October, scientists in India reported a new extraction method
for sea buckthorn berries giving a juice rich in vitamin C,
polyphenols and flavonoids.
The
research, published in the Journal of the Science of
Food and Agriculture (Vol. 86, pp. 2345-2353) reported using
continuous high speed centrifugation (spinning) to separate the
juice and the solid sludge the resulting juice retains more than
40 per cent of polyphenols, 50 per cent of flavonoids and 70 per
cent of vitamin C present in the pulp of the red berries.
Source:
European Journal of Clinical Nutrition
Advance
online publication 27 June 2007; doi: 10.1038/sj.ejcn.1602831
"Effects of sea buckthorn berries on infections and
inflammation: a double-blind, randomized, placebo-controlled
trial"
Authors:
P. Larmo, J. Alin, E. Salminen, H. Kallio and R Tahvonen
|